Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

The Summit for Cancer Immunotherapy (Summit4CI), June 26–29, 2016 Halifax, Canada

This is a preview of subscription content, log in to check access.

Abbreviations

CAR:

Chimeric antigen receptor

CCIC:

Canadian Cancer Immunotherapy Consortium

CRISPR:

Clustered regularly interspaced short palindromic repeats

CTLA4:

Cytotoxic T lymphocyte-associated protein-4

DC:

Dendritic cell

FZD5:

Frizzled class receptor 5

HER2:

Human epidermal growth factor receptor-2

IFN:

Interferon

IL:

Interleukin

IRE-1:

Inositol-requiring enzyme-1

MEK:

Mitogen-activated protein kinase

MHC:

Major histocompatibility complex

NK:

Natural killer

NKT:

Natural killer T

PD-1:

Programmed cell death protein-1

PD-L:

Programmed death ligand

RAS:

RAS-type GTPase family

RGMb:

Repulsive guidance molecule b

RNF43:

Ring finger protein 43

TAC:

T cell antigen coupler

TEX:

Tumor-derived exosomes

TIL:

Tumor-infiltrating lymphocytes

TIM-3:

T cell immunoglobulin and mucin domain 3

TME:

Tumor microenvironment

T-Vec:

Talimogene laherparepvec

VSV:

Vesicular stomatitis virus

XBP1:

X-box binding protein-1

Author information

Correspondence to Connie. M. Krawczyk.

Ethics declarations

Conflict of interest

The authors declare no conflicts of interest. Connie Krawczyk participated in the organization of this meeting as coordinator of knowledge dissemination and outreach.

Additional information

Maartje C. A. Wouters, Jeanette E. Boudreau, and Connie. M. Krawczyk contributed equally.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wouters, M.C.A., Laumont, C.M., Chen, B. et al. The Summit for Cancer Immunotherapy (Summit4CI), June 26–29, 2016 Halifax, Canada. Cancer Immunol Immunother 66, 811–818 (2017). https://doi.org/10.1007/s00262-017-1996-9

Download citation

Keywords

  • Cancer
  • Immunotherapy
  • Oncolytic virus
  • Tumor microenvironment
  • Precision medicine
  • Cancer genetics